Results 61 to 70 of about 3,594 (173)

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Acta Dermato-Venereologica, 2019
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs.
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, Matthias Borowski, Caroline Forner, Joachim Gerss, Martin Metz, Petra Staubach, Ulrike Raap, Martin Kaatz, Marc Urban, Thomas A. Luger, Sonja Ständer   +12 more
doaj   +1 more source

Aprepitant loaded solid preconcentrated microemulsion for enhanced bioavailability: A comparison with micronized Aprepitant

European Journal of Pharmaceutical Sciences, 2015
Aprepitant (APT) is a lipophilic, poorly water soluble drug with moderate permeability characteristic. Therefore, we aimed to improve solubility as well as permeability that could possibly improve oral bioavailability of APT. For this purpose, Quality by design (QbD) approach employing simplex lattice mixture design was used to prepare solid ...
Sunil, Kamboj, Radhika, Sharma, Kuldeep, Singh, Vikas, Rana   +3 more
openaire   +2 more sources

Cytotoxic and apoptotic effects of neurokinin-1 receptor (NK1R) antagonist on multiple myeloma cells [PDF]

مجله علمی دانشگاه علوم پزشکی کردستان, 2019
Background and Aim: Despite therapeutic improvements in recent decades, multiple myeloma (MM) still remains as one of the leading causes of death all over the world. Previous studies have indicated role of neurokinin-1 receptor (NK1R) in the pathogenesis
Elham Razani, Davood Bashash
doaj   +1 more source

Aprepitant exposure and long-term prognosis in breast cancer: a propensity-score-matched cohort study

European Journal of Medical Research
Background Whether the neurokinin-1 receptor (TACR1) antagonist aprepitant confers oncologic benefit beyond antiemesis remains uncertain. We evaluated the association between aprepitant exposure during adjuvant chemotherapy and long-term outcomes in ...
Limin Pan, Zhiyuan Zhang, Wanyue Li, Feng Lv, Yuanxiang Lu, Yimin Liu   +5 more
doaj   +1 more source

Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant

Case Reports in Oncology, 2014
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation.
Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert   +6 more
doaj   +1 more source

The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages

Drug Design, Development and Therapy, 2020
Xiao-nan Zhao,* Zhen-zi Bai,* Cheng-hua Li, Chuan-lun Sheng, Hong-yan Li Department of Infectious, The Third Hospital of Jilin University, Changchun City, Jilin Province 130033, People’s Republic of China*These authors contributed equally to this ...
Zhao X, Bai Z, Li C, Sheng C, Li H
doaj  

Antitumor Strategies Targeting Peptidergic Systems

Encyclopedia
Peptidergic systems show promise as targets for fighting tumors. While some peptides encourage the growth and spread of tumor cells and angiogenic mechanisms, others display antitumor properties. As such, peptide ligands and receptor antagonists could be
Francisco D. Rodríguez, Rafael Coveñas
doaj   +1 more source

Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy

Egyptian Liver Journal
Background HCC (Hepatocellular carcinoma) is the most common primary malignant cancer in the liver. Treatment options to incurable HCC such as sorafenib, an oral multikinase inhibitor, had numerous side effects and questionable effectiveness.
Heba E. Sedky, Yasmine N. Elwany, Eman S. El Alfy, Mona N. Elwany, Yasmin M. Nabil, Hazem F. Manna, Mohamed A. Abdelaziz, Wessam F. El Hadidy   +7 more
doaj   +1 more source

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting

Journal of Research in Medical Sciences, 2015
Background: Depending on the site of irradiation, about 40-80% of patients undergoing radiotherapy (RT) will experience nausea and/or vomiting. The current study aimed to investigate the efficacy of ondansetronas as a single agent and with a combination ...
Hamid Emami, Simin Hematti, Seyed Masoud Saeidian, Awat Feizi, Shahin Taheri, Pourya Adeli, Golshan Mahmoudi   +6 more
doaj  

Aprepitant [PDF]

, 2020
openaire   +1 more source